Heart failure therapy at the turn of the century

Heart Failure Reviews

Volumn 6, Issue 1, 2001, Pages 7-14

  Goldstein Md, Sidney ^a  

^a Division of Cardiovascular Medicine   (United States)

Author keywords

ACEI; Beta blockers; Heart failure

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN I; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; BUMETANIDE; CAPTOPRIL; CARVEDILOL; DIGITALIS; DIGITALIS GLYCOSIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; FUROSEMIDE; LISINOPRIL; LOOP DIURETIC AGENT; LOSARTAN; METOPROLOL; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TORASEMIDE; UNINDEXED DRUG; VASODILATOR AGENT;

ANGIONEUROTIC EDEMA; CELL TRANSPLANTATION; CLINICAL TRIAL; CONFERENCE PAPER; COUGHING; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG MECHANISM; ELECTROSTIMULATION THERAPY; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE REMODELING; HUMAN; METABOLIC INHIBITION; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SODIUM ABSORPTION; SODIUM RESTRICTION; TREATMENT OUTCOME;

FORECASTING; HEART FAILURE, CONGESTIVE; HUMANS; MYOCARDIAL CONTRACTION; VENTRICULAR DYSFUNCTION, LEFT;

EID: 0035064104     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1009847006280     Document Type: Conference Paper

References (53)

1. Hospitalization of patients with heart failure: National Hospital Discharge Survey, 1985 to 1995
2. Economic impact of heart failure in the United States: Time for a different approach
3. Epidemiology of heart failure
4. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators
5. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group
6. Effects of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure
7. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure
8. Oral amrinone for the treatment of chronic congestive heart failure: Results of a multicenter randomized double-blind and placebo-controlled withdrawal study
9. Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group
10. Efficacy of phosphodiesterase inhibition with milrinone in combination with converting enzyme inhibitors in patients with heart failure. The Milrinone Multicenter Trials Investigators
11. Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group
12. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study
13. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative studies Group
14. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group
15. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial
16. The effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF)
17. Diuretic treatment for the sodium retention of congestive heart failure
18. Effect of diuresis on the performance of the failing left ventricle in man
19. Furosemide absorption altered in decompensated congestive heart failure
20. Potentiation of furosemide by metolazone in refractory edema
21. The physiologic basis of diuretic synergism: Its role in treating diuretic resistance
22. Cardiovascular death and left ventricular remoldeling two years after myocardial infarction. Baseline predictors and impact of long-term use of captopril: Information from the survival and ventricular enlargement (SAVE) trial
23. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure
24. The renin-angiotensin system and cardiac hypertrophy
25. Reaction and reparative myocardial fibrosis in arterial hypertension in the rat
26. Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart
27. Angiotensin II-forming pathways in normal and failing human hearts
28. Captopril-induced changes in prostaglandin production: Relationship to vascular responses in normal man
29. Determinants of angiotensin II generation during converting enzyme inhibition
30. Effects of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions
31. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators
32. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. ATLAS Study Group
33. Effect of angiotensin converting enzyme inhibition in renovascular hypertensin
34. Heart Failure Society of America (HFSA) practice guidelines. HFSA guidelines for management of patients with heart failure caused by left ventricular systolic dysfunction - Pharmacological approaches
35. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results
36. A randomized trial of propranolol in patients with acute myocardial infarction. II. Morbidity results
37. Effect of propranolol after acute myocardial infarction in patients with congestive heart failure
38. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure
39. Time course of improvement in left ventricular function, mass and geometry in patients with congestive heart failure treated with beta-adrenergic blockade
40. Effect of metoprolol on myocardial function and energetics in patients with nonischemic dilated cardiomyopathy: A randomized, double-blind, placebo-controlled study
41. Comparative effects of beta-adrenergic blocking drugs on experimental ventricular fibrillation threshold
42. Long-term therapy with metoprolol attenuates cardiomyocyte apoptosis in dogs with heart failure
43. Functional significance of NA-K-ATPase in the kidney: Effects of ouabain inhibition
44. Acetylstrophanthidin-induced reflex inhibition of canine renal sympathetic nerve activity mediated by cardiac receptors with vagal afferents
45. Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings
46. Suppression of the renin-angiotensin system by intravenous digoxin in chronic congestive heart failure
47. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: Results of the PROVED trial. PROVED Investigative Group
48. Withdrawal of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. RADIANCE Study
49. The effect of digoxin on mortality and morbidity in patients with heart failure. The Digitalis Investigation Group
50. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effects of ramipril
51. Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis
52. Losartan Heart Failure Survival Study-ELITE II
53. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators